AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1.   (original) A composition comprising solifenacin or a salt thereof, wherein a compound represented by the formula (I) including optical isomers thereof

(I)

[in the formula, R^1 represents an optionally substituted lower alkyl; the same applies hereinbelow] or a salt thereof is contained in a total amount of less than 1% to solifenacin or a salt thereof.

2.   (original) A composition according to claim 1, wherein a compound represented by the formula (I) including optical isomers thereof or a salt thereof is contained in a total amount of less than 0.7% to solifenacin or a salt thereof.

3.   (original) A composition according to claim 1, where a compound represented by the formula (I) including optical isomers thereof or a salt thereof is contained in a total amount of less than 0.1% to solifenacin or a salt thereof.

4.   (currently amended) A composition according to claim 1 ~~any one of claims 1, 2 and 3~~, wherein R^1 is ethyl.

5.   (currently amended) A composition according to claim 1 ~~any one of claims 1, 2 and 3~~, wherein R^1 is methyl or benzyl

2

6.   (currently amended) A composition according to <u>claim 1</u> any one of claims 1 to 5, as produced by a production method comprising reacting a compound represented by the formula (II)

(II)

[in the formula, R^1 represents a lower alkyl] and (R)-quinuclidin-3-ol in the presence of an alkali metal lower alkoxide.

7.   (currently amended) A method for producing a composition according to <u>claim 1</u> any one of claims 1 to 5, comprising reacting a compound represented by the formula (II) according to claim 6 and (R)-quinuclidin-3-ol in the presence of an alkali metal lower alkoxide.

8.   (currently amended) A composition according to <u>claim 1</u> any one of claims 1 to 5, which is a pharmaceutical composition.

9.   (original) A composition according to claim 6, which is a pharmaceutical composition.